In the EMPEROR-Reduced Trial [13], of 3730 heart failure patients with a reduced ejection fraction (≤40%), the use of empagliflozin, an SGLT-2 inhibitor, was compared with a placebo over a median duration of 16 months. The gene discussed is SLC5A2; the disease is heart failure.